Serum cytokine profiles predict survival benefits in patients with advanced hepatocellular carcinoma treated with sorafenib: a retrospective cohort study

[1]  M. Honda,et al.  Blood neutrophil to lymphocyte ratio as a predictor in patients with advanced hepatocellular carcinoma treated with hepatic arterial infusion chemotherapy , 2015, Hepatology research : the official journal of the Japan Society of Hepatology.

[2]  A. Jemal,et al.  Global cancer statistics, 2012 , 2015, CA: a cancer journal for clinicians.

[3]  P. Schirmacher,et al.  Human and mouse VEGFA-amplified hepatocellular carcinomas are highly sensitive to sorafenib treatment. , 2014, Cancer discovery.

[4]  X. Wang,et al.  Cancer stem cells in the development of liver cancer. , 2013, The Journal of clinical investigation.

[5]  Tohru Utsunomiya,et al.  FGF3/FGF4 amplification and multiple lung metastases in responders to sorafenib in hepatocellular carcinoma , 2013, Hepatology.

[6]  B. Chauffert,et al.  EGFR activation is a potential determinant of primary resistance of hepatocellular carcinoma cells to sorafenib , 2012, International journal of cancer.

[7]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[8]  J. Bruix,et al.  Plasma Biomarkers as Predictors of Outcome in Patients with Advanced Hepatocellular Carcinoma , 2012, Clinical Cancer Research.

[9]  M. Honda,et al.  Randomized, Phase II Study Comparing Interferon Combined with Hepatic Arterial Infusion of Fluorouracil plus Cisplatin and Fluorouracil Alone in Patients with Advanced Hepatocellular Carcinoma , 2011, Oncology.

[10]  J. Llovet,et al.  Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling , 2008, Molecular Cancer Therapeutics.

[11]  Dieter Häussinger,et al.  Sorafenib in advanced hepatocellular carcinoma. , 2008, The New England journal of medicine.

[12]  Xin Wei Wang,et al.  Prediction of venous metastases, recurrence, and prognosis in hepatocellular carcinoma based on a unique immune response signature of the liver microenvironment. , 2006, Cancer cell.

[13]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[14]  A. Jemal,et al.  Global Cancer Statistics , 2011 .

[15]  Yoon-Koo Kang,et al.  Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. , 2009, The Lancet. Oncology.